Skip to search formSkip to main contentSkip to account menu

grazoprevir

Known as: (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide 
National Institutes of Health

Related topics

Related topics

6 relations
Breast Cancer Resistance Protein Inhibitors [MoA]HCV NS3/4A Protease Inhibitors [MoA]Hepatitis Celbasvir / grazoprevir

Broader (1)

MK-5172

Narrower (1)

Zepatier

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS.
2019
2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in sub‐Saharan Africa and the Middle East, particularly in Egypt… 
2018
2018
Simultaneous Determination of Elbasvir and Grazoprevir in Their Pharmaceutical Preparation Using High-Performance Liquid Chromatographic Method.
A high-performance liquid chromatographic method has been developed for simultaneous determination of elbasvir and grazoprevir… 
2018
2018
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
BackgroundThe prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is high and results in a poor prognosis… 
Review
2017
Review
2017
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Hepatitis C is the leading cause of progressive liver fibrosis worldwide and results in cirrhosis, liver cancer, liver failure… 
2017
2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure
People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging… 
Highly Cited
2016
Highly Cited
2016
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24…
BACKGROUND The phase 2 C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy) demonstrated a 96.2… 
Review
2016
Review
2016
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection
ABSTRACT Introduction: Hepatitis C virus (HCV)-related liver disease is a cause of significant morbidity and mortality worldwide… 
Review
2016
Review
2016
Elbasvir/Grazoprevir
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly… 
Review
2016
Review
2016
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4
ABSTRACT Introduction: During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)